Kevin J. Filipski

Publications by Year

Research Areas

Pancreatic function and diabetes, Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Blood Coagulation and Thrombosis Mechanisms, Biochemical and Molecular Research

Most-Cited Works

• → Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus(2011)115 cited
• → Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle(2009)80 cited
• → Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus(2011)68 cited
• → A versatile copper-catalyzed coupling reaction of pyridin-2(1H)-ones with aryl halides(2006)56 cited
• → Intestinal Targeting of Drugs: Rational Design Approaches and Challenges(2013)54 cited
• → Novel and selective spiroindoline-based inhibitors of sky kinase(2011)48 cited
• → The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus(2012)44 cited
• → The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus(2013)40 cited
• → The Discovery of (2R,4R)‐N‐(4‐chlorophenyl)‐N‐ (2‐fluoro‐4‐(2‐oxopyridin‐1(2H)‐yl)phenyl)‐4‐methoxypyrrolidine‐1,2‐dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor(2007)39 cited
• → Selective pharmacological inhibition of the sodium-dependent phosphate cotransporter NPT2a promotes phosphate excretion(2020)38 cited